cancer immunotherapy program 2 (Flexus Biosciences)

N/A

Report date: 2025/06/11 11:29:45
NME

Base Information

Drug Namecancer immunotherapy program 2 (Flexus Biosciences)
Drug Alias Namecancer immunotherapy program 2 (FLX Bio)USP7 inhibitors (FLX Bio)USP-055USP-7-217
ClassificationSmall molecules
Mechanisms of ActionUbiquitin carboxyl-terminal hydrolase 7 inhibitorsImmunostimulants
TargetsUbiquitin carboxyl-terminal hydrolase 7
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesFlexus Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesRapt Therapeutics Inc
Inactive CompaniesFlexus Biosciences Inc
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A